Analytical method development and validation for the quantitative analysis of Ibrutinib in API form and marketed pharmaceutical dosage form by using RP-HPLC
Authors
Article Information
Publication Timeline
- Published
Abstract
A simple, rapid, specific and accurate reverse phase high performance liquid chromatographic method has been developed for the validated of Ibrutinib in bulk as well as in marketed pharmaceutical dosage form. This separation was performed on a Symmetry ODS C18 (4.6×250mm, 5µm) column with Methanol: Phosphate Buffer (35:65) v/v as mobile phase at a flow rate of 1.0 mL min−1 with UV detection at 235 nm; the constant column temperature was Ambient. The runtime under these chromatographic conditions was less than 8 min. The retention time of Ibrutinib was found to be 2.276min. The calibration plot was linear over the concentration range of 6–14 μg mL−1 with limits of detection and quantification values of 1.2 and 3.6 ng mL−1 respectively. The mean % assay of marketed formulation was found to be 99.86%, and % recovery was observed in the range of 98-102%. Relative standard deviation for the precision study was found <2%.The developed method is simple, precise, specific, accurate and rapid, making it suitable for estimation of Ibrutinib in bulk and marketed pharmaceutical dosage form dosage form.
How to Cite
Vishwanath, D., Sarkar, P., Islam, A., Salmankhan, & Sarkar, S. (2024). Analytical method development and validation for the quantitative analysis of Ibrutinib in API form and marketed pharmaceutical dosage form by using RP-HPLC. International Journal of Medical and All Body Health Research, 5(1), 31-37.
Vishwanath, D, et al. "Analytical method development and validation for the quantitative analysis of Ibrutinib in API form and marketed pharmaceutical dosage form by using RP-HPLC." International Journal of Medical and All Body Health Research, vol. 5, no. 1, 2024, pp. 31-37.
Vishwanath, D., Sarkar, P., Islam, A., Salmankhan and Sarkar, S. (2024) 'Analytical method development and validation for the quantitative analysis of Ibrutinib in API form and marketed pharmaceutical dosage form by using RP-HPLC', International Journal of Medical and All Body Health Research, 5(1), pp. 31-37.
Vishwanath D, Sarkar P, Islam A, Salmankhan, Sarkar S. Analytical method development and validation for the quantitative analysis of Ibrutinib in API form and marketed pharmaceutical dosage form by using RP-HPLC. International Journal of Medical and All Body Health Research. 2024;5(1):31-37.
Similar Articles
- Formulation and in vitro evaluation of Diltiazem controlled release tablets Vol 5, Issue 1 (2024)
- Development and validation of a new analytical RP-HPLC method for the determination of flavoxate hydrochloride in bulk form and pharmaceutical dosage form Vol 5, Issue 1 (2024)
- Formulation and evaluation of Pregabalin microspheres Vol 5, Issue 1 (2024)
- Evaluating the Quality of Health Services Provided to Pregnant Women at Sudanese Family Planning Association, El-Fateh El-Nour Clinic in El-Obeid City, North Kordofan State, Sudan Vol 5, Issue 1 (2024)
- Health education in Vietnamese federal schools: Content and methodology Vol 5, Issue 1 (2024)
Find this Article on
Google Scholar Semantic Scholar OpenAlex ResearchGate BASEA newly published article may take a few days to appear on these services.